The peptides most discussed for energy in research include MOTS-c, Selank, BPC-157, and AOD-9604, but nearly all supporting evidence comes from animal studies or very small human trials. No research peptide sold online is FDA-approved for energy or fatigue. Buyers should treat these compounds as experimental and consult a licensed clinician before any use.
How We Ranked These Compounds
This guide ranks peptides by the quality and size of available evidence, not by popularity or vendor marketing. The tiers we use are: human randomized controlled trials (RCTs), small human studies or open-label trials, animal studies, and in-vitro (cell culture) work. A compound with one rodent study sits far below one with multiple human trials, even if the rodent results look dramatic.
We also looked at the plausibility of the proposed mechanism, whether the compound has any approved pharmaceutical form, and how honestly the research community discusses its limitations. Every compound on this list is sold as a research chemical in the United States. None of them are FDA-approved treatments for fatigue, low energy, or any related condition. That framing matters because it shapes what a buyer can reasonably expect.
One more note on sourcing: peptide vendors frequently cite studies on related but distinct molecules, or extrapolate animal data to human outcomes without saying so. We flag those gaps wherever they appear.
MOTS-c: The Mitochondrial Peptide With the Most Interesting Human Data
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first described by Lee et al. in a 2015 Cell Metabolism paper. The original research showed that MOTS-c regulates glucose metabolism and improves exercise capacity in mice. That animal work generated significant interest because the mechanism, activating AMPK and improving mitochondrial efficiency, is directly relevant to cellular energy production.
Human data is limited but exists. A 2019 study published in Nature Communications (Kim et al., sample size 70) found that circulating MOTS-c levels in humans decline with age and correlate with metabolic health markers. Separately, a small 2021 clinical study examined MOTS-c in older adults and reported improvements in physical performance metrics, though the sample was small enough that results should be treated as preliminary. No large RCT has confirmed these findings.
The honest caveat here is that endogenous MOTS-c levels correlating with health outcomes does not mean that injecting exogenous MOTS-c produces the same effect. That logical gap is common in peptide research and buyers should keep it in mind. MOTS-c is not FDA-approved for any use.
Selank: Anxiolytic Peptide With Soviet-Era Human Trials
Selank is a synthetic heptapeptide derived from the immune peptide tuftsin. It was developed in Russia and has been studied there since the 1990s, primarily for anxiety and cognitive function rather than energy directly. The connection to energy is indirect: Selank appears to modulate BDNF expression and stabilize enkephalins, which researchers have proposed may reduce fatigue associated with chronic stress.
Several Russian clinical trials, published in journals including Eksperimental'naya i Klinicheskaya Farmakologiya, reported reduced anxiety and improved mental performance in patients with generalized anxiety disorder. Sample sizes in these trials ranged from roughly 60 to 200 participants. The limitation is that most of this research has not been replicated in Western peer-reviewed RCTs, and the trials were not always blinded or placebo-controlled by modern standards.
Selank is approved as a drug in Russia but holds no FDA approval or equivalent status in the United States. Buyers in the U.S. are purchasing it as an unregulated research compound. The fatigue-reduction angle is plausible given the stress-modulation mechanism, but direct energy-outcome data in healthy adults is essentially absent.
BPC-157: Healing Peptide With Indirect Energy Claims
BPC-157 (Body Protection Compound 157) is a 15-amino-acid peptide derived from a protein found in gastric juice. The bulk of its research, reviewed in a 2018 Current Pharmaceutical Design paper by Sikiric et al., covers wound healing, tendon repair, and gut protection in rodent models. The energy connection is secondary: proponents argue that better gut health and reduced systemic inflammation translate to improved energy levels.
That chain of reasoning is speculative. There are no published human RCTs on BPC-157 for energy or fatigue. A handful of small human studies have examined it for inflammatory bowel conditions, but those trials used oral formulations and focused on GI endpoints, not energy. The FDA has not approved BPC-157 in any form, and in 2022 the agency issued guidance indicating that BPC-157 cannot be used in compounded drugs.
BPC-157 ranks lower on this list precisely because its energy-related claims are the most indirect. The rodent healing data is genuinely interesting, but extrapolating it to human energy outcomes requires several unsupported inferential steps. Buyers drawn to BPC-157 for energy specifically are working with the thinnest evidence on this list.
AOD-9604: A Fragment With Metabolic Research but Limited Energy Data
AOD-9604 is a modified fragment of human growth hormone (hGH), specifically the C-terminal region (amino acids 176-191). It was originally developed by Metabolic Pharmaceuticals in Australia and studied in several human trials for obesity. A 2001 paper in the American Journal of Physiology reported fat-reduction effects in obese rodents. Human trials followed, including a 12-week RCT published in Obesity Research in 2004 with 300 participants, which found modest weight effects but did not meet the primary endpoint.
The energy connection comes from the metabolic pathway: AOD-9604 is thought to stimulate lipolysis without the insulin-desensitizing effects of full hGH, which theoretically could improve energy substrate availability. However, no published trial has used energy or fatigue as a primary outcome. The compound is not FDA-approved. Metabolic Pharmaceuticals discontinued development after the Phase 3 trials underperformed.
AOD-9604 has more human trial data than most peptides on this list, which is why it appears here, but that data addresses weight and metabolism rather than subjective energy. Buyers should be clear-eyed that the energy narrative is an extrapolation from metabolic mechanisms, not a finding from controlled trials.
What Buyers Should Actually Consider Before Purchasing
Every compound on this list is a research chemical in the United States. That means no standardized manufacturing requirements, no required purity testing, and no regulatory oversight of vendor claims. Third-party certificate of analysis (COA) documents from an independent lab are the minimum quality signal worth checking. Even then, a COA confirms what's in the vial on the day it was tested, not what you'll receive.
The evidence gap between animal studies and human outcomes is real and wide. Rodent metabolism differs from human metabolism in ways that matter for peptide pharmacokinetics. A compound that reliably raises energy markers in mice may do nothing in humans, or may produce effects that weren't studied in animals. That's not a reason to dismiss the research, but it is a reason to weight it appropriately.
Anyone considering these compounds should speak with a licensed physician or endocrinologist first. Fatigue has many causes, most of which have evidence-based treatments that don't require purchasing unregulated research chemicals. Peptides may be worth researching, but they sit at the end of a long list of better-studied options.
How we evaluate
- Evidence tier Is the research preclinical (animal), limited human trials, or robust human data? We label each.
- Regulatory status Is the compound FDA-approved for any human use? Most are not. We state it plainly for each entry.
- Mechanism transparency Is the proposed mechanism understood, or is it theoretical? We separate the two.
- Vendor documentation Any vendor we link must supply batch-linked third-party COAs and make no human-use claims.
- Claim integrity We describe research findings as findings, never as guaranteed human outcomes.
The compounds covered in these guides are classified as research chemicals. None are approved by the FDA for human use, human consumption, or the treatment of any condition. They are sold legally only for laboratory and in vitro research purposes.
Affiliate disclosure: the link below is sponsored. We may earn a commission if you buy through it, at no cost to you. It does not affect our picks or scores.
See this month's top-rated picksFrequently asked questions
Are any peptides FDA-approved for energy or fatigue?
No peptide is currently FDA-approved specifically for energy or fatigue. Some peptides have approved pharmaceutical forms for other indications (for example, bremelanotide is approved as Vyleesi for hypoactive sexual desire disorder), but none of those approvals cover energy. Research peptides sold online are not approved treatments for any condition.
How is MOTS-c different from other energy peptides?
MOTS-c is unusual because it's encoded in mitochondrial DNA rather than nuclear DNA, making it a mitochondria-derived peptide (MDP). Its proposed mechanism, activating AMPK to improve cellular energy metabolism, is more directly tied to energy production at the cellular level than the mechanisms proposed for most other peptides on this list. That said, human trial data remains limited to small studies, and no large RCT has confirmed the animal findings.
Why does BPC-157 appear on energy lists if its research is about healing?
BPC-157 appears on energy-focused lists primarily because of vendor marketing that links gut health and reduced inflammation to improved energy levels. That connection is biologically plausible in a general sense, but no published human study has tested BPC-157 against energy or fatigue outcomes. Buyers should recognize that the energy claim is an inference from healing research, not a direct finding.
Sources
- Lee et al., 2015, Cell Metabolism, MOTS-c original discovery Foundational MOTS-c mitochondrial peptide study
- Kim et al., 2019, Nature Communications, MOTS-c and aging in humans Human circulating MOTS-c and metabolic health
- Sikiric et al., 2018, Current Pharmaceutical Design, BPC-157 review Comprehensive BPC-157 preclinical evidence review
- Heffernan et al., 2001, American Journal of Physiology, AOD-9604 in rodents AOD-9604 lipolysis and fat metabolism in animals
Educational and informational content only. This is not medical advice, diagnosis, or treatment guidance. The compounds discussed are research compounds not approved by the FDA for human use, human consumption, or the treatment of any condition outside prescribed contexts. Consult a licensed clinician before making any health-related decision.
